Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$580 Mln
Revenue (TTM)
$77 Mln
Net Profit (TTM)
$-30 Mln
ROE
-0.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
9.8
Industry P/E
--
EV/EBITDA
-13.6
Div. Yield
0 %
Debt to Equity
1.8
Book Value
$0.8
EPS
$-1
Face value
--
Shares outstanding
47,549,200
CFO
$-181.69 Mln
EBITDA
$-176.08 Mln
Net Profit
$-261.94 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Apollo Endosurgery (APEN)
| 0.3 | 0.8 | 1.2 | 65.6 | 66.4 | 11.7 | -30.6 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Apollo Endosurgery (APEN)
| 18.3 | 147.9 | 19.3 | -17.4 | -38.2 | -53.9 | -30.5 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy. The company offers OverStitch and OverStitch Sx Endoscopic Suturing... Systems that enable advanced endoscopic procedures by allowing physicians to suture and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying, which assists the patient in losing weight under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. In addition, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical service providers, hospitals, outpatient surgical centers, clinics, and physicians in the United States, Costa Rica, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas. Read more
CEO, Pres & Director
Mr. Charles S. McKhann
CEO, Pres & Director
Mr. Charles S. McKhann
Headquarters
Austin, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Apollo Endosurgery Inc (APEN) is $10.00 (NASDAQ) as of 10-Apr-2023 09:30 EDT. Apollo Endosurgery Inc (APEN) has given a return of 66.41% in the last 3 years.
Since, TTM earnings of Apollo Endosurgery Inc (APEN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-10.26
|
12.54
|
|
2021
|
-10.25
|
4.13
|
|
2020
|
-3.46
|
11.58
|
|
2019
|
-2.29
|
29.53
|
|
2018
|
-1.51
|
2.39
|
The 52-week high and low of Apollo Endosurgery Inc (APEN) are Rs -- and Rs -- as of 03-Apr-2026.
Apollo Endosurgery Inc (APEN) has a market capitalisation of $ 580 Mln as on 11-Apr-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Apollo Endosurgery Inc (APEN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.